Skoči na glavni sadržaj

Pregledni rad

https://doi.org/10.15644/asc59/4/9

Impaired Gustation in Liver Diseases: A Comprehensive Narrative Literature Review

Aleksandra Kędziora-Ciechańska ; Odjel za oralnu medicinu Medicinskog sveučilišta u Lublinu, Poljska; Medicinski fakultet Medicinskog sveučilišta u Lublinu, Poljska
Krystian Ciechański ; Odjel za gastroenterologiju Regionalne specijalističke bolnice u Lublinu, Poljska; Odjel za toksikologiju Medicinskog sveučilišta u Lublinu, Poljska; Medicinski fakultet Medicinskog sveučilišta u Lublinu, Poljska *
Renata Chałas ; Odjel za oralnu medicinu Medicinskog sveučilišta u Lublinu, Poljska

* Dopisni autor.


Puni tekst: engleski pdf 329 Kb

str. 426-439

preuzimanja: 467

citiraj

Puni tekst: hrvatski pdf 329 Kb

str. 426-439

preuzimanja: 88

citiraj


Sažetak

Objective: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is one of the fastestgrowing liver disorders worldwide. It is driven by obesity and type 2 diabetes. Taste perception plays a key role in appetite regulation and nutrition, also influencing other liver diseases progression. This review summarizes past and current evidence on taste disorders in liver diseases and their clinical implications. Materials and Methods: A narrative review of PubMed, Web of Science, Google Scholar, and ResearchGate databases was conducted using selected MeSH terms. Results: Taste disturbances have been reported in viral hepatitis, cirrhosis, Wilson’s disease, amebic liver abscesses, and NAFLD/MASLD, as well as in nutritional deficiencies (zinc, magnesium, vitamin A, branchedchain amino acids). Dysgeusia was linked to reduced appetite, sarcopenia, malnutrition, altered food preferences, and obesity risk in MASLD. Taste impairments worsen with liver dysfunction progression. Several drugs (e.g., interferon, metronidazole) contribute to dysgeusia. Zinc deficiency was the most consistent factor. Glucagon-like peptide-1 (GLP-1) receptor modulators, affecting appetite and sweet/umami perception, appear promising in MASLD therapy. Conclusions: Taste disorders are prevalent and still under-recognized in populations with liver diseases. The cause of these disorders remains unclear. Most of available studies affecting nutrients deficiencies are outdated. More research targeting molecular pathways of taste modulation (e.g., GLP-1 receptors), as well as determining the prevalence and clinical consequences of dysgeusia in specific liver disease stages is needed to better understand how micronutrient deficiencies and medications affect taste disorders.

Ključne riječi

Liver diseases; Dysgeusia; Taste perception; Taste disorders; Zinc; MASLD

Hrčak ID:

341920

URI

https://hrcak.srce.hr/341920

Datum izdavanja:

26.12.2025.

Podaci na drugim jezicima: hrvatski

Posjeta: 920 *